Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

导出原文传递

翻译打印收藏纠错

作者： de Vries, Tamar, I ^[1] ; Eikelboom, John W. ^[2] ; Bosch, Jackie ^[3] ; Westerink, Jan ^[4] ; Dorresteijn, Jannick A. N. ^[5] ; Alings, Marco ^[6] ; Dyal, Leanne ; Berkowitz, Scott D. ; van der Graaf, Yolanda ; Fox, Keith A. A. ; Visseren, Frank L. J.

作者单位： Bayer US LLC, Thrombosis, Clin Dev, Whippany, NJ USA ^[1] Amphia Hosp, Dept Cardiol, Langendijk 75, NL-4819 EV Breda, Netherlands ^[2] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Weg 100, NL-3584 CG ^[3] McMaster Univ, Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada ^[4] Univ Edinburgh, Ctr Cardiovasc Sci, 49 Little France Crescent, Edinburgh EH16 4TJ, Midlothian ^[5] Univ Utrecht, Univ Med Ctr Utrecht, Dept Vasc Med, POB 85500, NL-3508 GA Utrecht, Netherlands ^[6]

关键词 Life expectancy Predictive model Secondary prevention Treatment effect Antithrombotic therapy

发布时间 2021-06-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交